Taurine and Biological Age: Part Four: The Trial That Finished in Between

Abstract

While the argument described in Parts One to Three was running, a trial in Munich was quietly testing the original version of the claim. It gave 4 grams of taurine a day to adults aged 55 to 75 for six months and measured their biological age two ways.

It started in September 2024, when the hypothesis was widely accepted. It finished on 13 November 2025, by which time the hypothesis had been challenged twice. No results have been published.

This part closes the series with what the trial can settle, what it cannot, and how we intend to read it when it appears.

1.The Trial

Registry entry NCT06613542, sponsored by the Technical University of Munich, is a randomised, parallel-group, quadruple-masked intervention study: participants, investigators, care providers and outcome assessors all blinded.

Ninety women and men aged 55 to 75, with a body mass index between 22 and 30, took 4 grams of taurine daily or placebo for six months. It ran from 25 September 2024 to 13 November 2025, and the registry was last updated eight days after completion.

The two primary outcomes are change in biological age at six months, measured by proteome analysis and, independently, by DNA methylation. Secondary outcomes include cognitive function and cardiometabolic risk.

Running two different biological-age clocks against each other in the same blinded participants is the strongest feature of the design. Methylation clocks are the standard currency of longevity research and also the most heavily marketed measurement in consumer wellness; a proteomic clock disagreeing with a methylation clock would be a finding about the clocks, and worth knowing separately from anything about taurine.

The exclusion criteria define who the answer applies to: no diabetes, no severe chronic illness, no recent heart attack or stroke, no psychiatric disorder including depression or dementia, no weight change of five kilograms or more. This is a healthy, stable, older population with no deficiency to correct.

2.What Three Parts of Argument Did to This Trial

The trial was designed against Part One's claim: that taurine falls with age and restoring it slows ageing. Two subsequent findings bear on whether that is the right test.

Part Two found no association between taurine and age in 137 men, and suggested the original decline may have been driven by participants under 20. If taurine does not fall in this population, there is nothing to restore, and the trial becomes a test of supraphysiological dosing rather than of repletion.

Part Three suggests the relationship may be non-monotonic, with the informative group being the prefrail. The Munich trial excluded chronic illness and enrolled by age and body mass index, so its participants are likely to sit predominantly in the robust category — the group in which taurine was already highest and in which, on that account, supplementation would have least to do.

None of this invalidates the trial. It changes what a null result would mean. A null in Munich would not refute the frailty account; it would be consistent with it.

3.The Dose Problem, Which Cuts Both Ways

Four grams a day is far above dietary intake, and far below the monkey dose from Part One, which was 250 mg per kilogram — roughly 17.5 grams for a 70-kilogram adult.

There is also a pharmacological caveat the Montreal group raised in Part Two, and it applies directly here. Two weeks of taurine supplementation raises muscle taurine content by around 40 per cent in rodents; a human study found no increase in muscle taurine after seven days at 4.98 grams a day.

If oral taurine does not accumulate in human tissue the way it does in rodent tissue, then the mouse lifespan data may not transfer at any dose, and a trial at 4 grams may be testing something that never reaches the compartment where the mechanism was described.

The trial does not appear to include a tissue measurement. Blood taurine would at least establish that something was absorbed.

4.How We Will Read It

Do both clocks agree? Two primary outcomes were pre-specified. If proteomic age moves and methylation age does not, or the reverse, that is a result about measurement, and any report leading with the positive one should be read as marketing rather than science.

Is the primary outcome the one reported? Cognitive function and cardiometabolic risk are secondary here. The pattern we have documented repeatedly in this section — null primary, conclusion built on a secondary — is the single most common way a negative trial becomes a positive headline.

And how long until publication? A completed trial with a clearly positive result tends to appear quickly. Silence is weak evidence and not nothing; the taurine literature already contains one trial that finished and stayed unpublished long enough for us to file it as such.

5.Where the Series Leaves the Question

Four publications, three of which we read in full and one of which we could not.

Taurine extends lifespan in worms and mice and improves health measures in monkeys, at doses no human takes. Whether it falls across the human lifespan is disputed, with the strongest human dataset finding no association and identifying a plausible artefact in the original. A reframing exists that would reconcile the two, in 146 people, unreplicated. And a well-designed trial has finished without reporting.

That is not a compound with no evidence behind it. It is a compound whose evidence has been moving in one direction for two years, and the direction is away from the claim on the label.

Editorial Comment

Taurine is in Boost at 500 mg, and we would rather state the awkward part plainly than have a reader find it elsewhere. The hypothesis that made taurine a longevity ingredient has been challenged twice in eighteen months, once in the journal that published it.

We make no claim that taurine slows ageing, affects biological age, or extends anything, and no such claim is authorised in the European Union. Taurine has no approved health claim at all.

Our 500 mg is not a longevity dose and was never chosen as one. Munich uses 4 grams — eight times what we supply — and the monkey work used the equivalent of 17.5 grams a day. Anyone reading the ageing literature as a reason to take a taurine-containing product is reading doses that no such product delivers.

We will report the Munich result here when it publishes, including if it is null, and including if it makes our own ingredient look worse. That is easy to promise now, which is the only reason writing this series before the result is worth anything.

Nothing in this series is advice about ageing, and biological-age testing sold direct to consumers is not a diagnostic. The modifiable factors with randomised evidence behind them — sleep, exercise, hearing, blood pressure, alcohol — are the ones worth a conversation with a doctor, and they are free.